Skip to main content
Smart Investors Daily
EN

NYSE · ENFN

Enfusion, Inc.

Technology · Software - Application

$10.76

Down-$0.04 (-0.37%)

Updated Sep 11, 2026, 2:24 PM

SID Score

Composite research score

Smart Money

Institutional and insider signal

Market cap
1.02B
P/E ratio
301.68
Dividend yield
0.00%
52-week range
$7.83 – $11.80
Volume
2.46M
Avg. volume
1.17M

Price performance

ENFN price history

1M range · 0 trading sessions · Daily adjusted prices

ENFN does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest ENFN news

The latest Smart Investors Daily articles mentioning ENFN.

ENFN research

Overview

Company profile and research snapshot.

Company profile

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. The company also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
ENFN recent ratings
DateFirmRatingTarget
Jan 13, 2025William BlairMarket Perform
Dec 23, 2024Piper SandlerNeutral
Dec 18, 2024StifelBuy
Mar 13, 2024B of A SecuritiesUnderperform
Feb 28, 2024Goldman SachsSell
Open full forecast

News briefing

No generated briefing is available yet.

seekingalpha.com · Nov 12, 2025

Clearwater Analytics: Q3 Figures Show Enfusion Acquisition Brings Meaningful Growth

Clearwater Analytics is rated a Strong Buy, trading at a discount despite robust SaaS-driven growth and successful Enfusion integration. The Enfusion acquisition doubled CWAN's total addressable market, enhanced platform capabilities, and improved revenue visibility with a 98% retention rate. CWAN's scalable SaaS model, strong EBITDA, and aggressive debt paydown strategy mitigate concerns over its $800 million debt load.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.